PANCREATIC DUCTAL ADENOCARCINOMA

This study tests a wearable device that creates electric fields (TTFields) combined with chemotherapy for people with metastatic pancreatic cancer that has spread. The goal is to see if adding the device to standard chemo is safe and can help control the disease. About 30 adults …

This study is for people with metastatic pancreatic cancer that has spread. It tests a new way of giving two standard chemotherapy treatments, switching between them each month. The goal is to see if this alternating schedule helps keep the cancer from growing longer than usual. …

This study tests a new oral drug, VS-7375, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS G12D mutation. The trial will first find the safest dose, then check if the drug shrinks tumors when used alone or with other ca…

This study tests an experimental pill called IPN01194 in adults with advanced solid tumors (cancers that have spread). The goal is to find the right dose and see if it is safe and can shrink tumors. About 220 people with specific genetic mutations will take the drug by mouth. Thi…

This expanded access program offers ELI-002 7P immunotherapy to patients with pancreatic cancer that has specific KRAS or NRAS gene mutations and who are at high risk of the cancer returning after surgery. The treatment aims to stimulate the immune system to fight any remaining c…

This study tests a new drug called AZD0901, alone or with other cancer drugs, in people with advanced solid tumors that have a specific protein (CLDN18.2). The goal is to see if the drug is safe and can shrink tumors. About 224 adults with stomach, bile duct, or pancreatic cancer…

This study is testing several new experimental drugs (RAS(ON) inhibitors) combined with standard chemotherapy or other targeted therapies for people with advanced colorectal or pancreatic cancer. The goal is to see if these combinations are safe and can shrink tumors. About 1,130…

This study tests two experimental drugs, elironrasib and daraxonrasib, given alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drugs are safe and can shrink or control tumors. About 534 adults with lung, col…

This study tests a more thorough surgery technique called total mesopancreas excision for people with pancreatic head cancer. The goal is to remove more of the tissue around the tumor to lower the chance of cancer coming back. Researchers will follow 90 patients for two years to …

This study tests a new drug called MK-2870, alone or with other cancer treatments, for people with advanced colorectal, pancreatic, or bile duct cancers that have spread or cannot be removed by surgery. The main goals are to check the drug's safety and see how many patients' tumo…

This early-phase trial tests whether fecal microbial transplants (healthy stool microbes) are safe and can help control pancreatic cancer. Ten patients scheduled for tumor-removal surgery will receive the transplant. The goal is to see if changing gut bacteria can improve outcome…

This study tests an experimental drug called ART0380 in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to find a safe dose and see if it works alone or with other chemotherapy drugs like gemcitabine or irinotecan. About 442 participants wi…

This study tests an experimental drug, LY3962673, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific genetic change called KRAS G12D. The goal is to find safe doses and see if the drug shrinks tumors, both alone and with other …

This early-phase trial tests a new drug called JANX008 in adults with advanced solid tumors (like lung, kidney, breast, or colorectal cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shri…

This study tests whether using a special surgical glue (Glubran® 2) during pancreas surgery can prevent dangerous fluid leaks. About 194 adults with pancreatic or related cancers who need surgery will be randomly assigned to receive the glue or standard care. The main goal is to …

This early-phase study tests a new treatment for people with metastatic pancreatic or breast cancer that has stopped responding to standard therapies. The treatment combines two chemotherapy drugs with high-dose vitamins and a stem cell transplant to help the body recover. The ma…

This study tests a new approach for people with advanced pancreatic cancer that cannot be removed by surgery. It combines a procedure that uses heat to destroy tumors (radiofrequency ablation) with standard chemotherapy and an immunotherapy drug (pembrolizumab). The goal is to se…

This early-stage trial tests a new medicine, BI 765049, in adults with advanced colorectal, stomach, or pancreatic cancer that cannot be removed by surgery or has spread. The main goal is to find the highest safe dose and best way to give the drug. BI 765049 is designed to help t…

This study tests whether adding a new targeted drug (BMS-986504) to standard chemotherapy can help people with a specific type of advanced pancreatic cancer live longer without their disease getting worse. The trial is for people whose tumors have a missing MTAP gene, which may m…

This study tests a combination of two immune-boosting drugs (CD40 and Dectin-1 activators) as a maintenance treatment for people with advanced pancreatic cancer that has not worsened after initial chemotherapy. About 100 adults whose cancer is either locally advanced or spread to…

This early-phase study tests a new drug (177Lu-DFC413) that delivers radiation directly to cancer cells in adults with advanced solid tumors like pancreatic, lung, breast, colorectal, and soft tissue cancers. The main goals are to check safety, find the right dose, and see if it …

This study tests whether adding a medical glue (Glubran 2) to the surgical connection in the pancreas can prevent a serious complication called pancreatic fistula, which is a leak of digestive fluids. About 100 adults having their pancreas removed due to cancer will be randomly a…

This early-stage trial tests a new drug called GV20-0251 in people with advanced solid tumors that no longer respond to standard treatments. The main goal is to check the drug's safety. About 10 adults with cancers like liver, lung, or skin cancer will take part. This is not a cu…

This early-phase study tests a new radioactive drug, [177Lu]Lu-NNS309, in adults with advanced pancreatic, lung, breast, or colorectal cancers that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink t…

This study tests a new drug, ASP5834, in people with advanced solid tumors that have certain changes in the KRAS gene. The goal is to find a safe dose and check for side effects. Some participants with colorectal cancer will also receive another drug called panitumumab. The study…

This study tests a new drug, Spevatamig, in people with advanced stomach, pancreatic, or bile duct cancers that cannot be removed by surgery or have spread. The trial has two parts: first, finding the safest dose of Spevatamig alone, then testing it combined with chemotherapy or …

This study tests a new drug called ASP2138 in people with a type of pancreatic cancer that can be removed by surgery. The drug helps the immune system attack cancer cells that have a specific protein (CLDN18.2). Participants receive ASP2132 two weeks before surgery, then standard…

This study tests a new drug called JPI-547 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. The goal is to find the safest dose and see if the combination helps shrink tumors. About 71 participants wil…

This study tests whether adding drugs that block the tumor's ability to hide from the immune system can make radiation therapy more effective for people with advanced pancreatic cancer. About 60 participants will receive standard radiation plus an immunotherapy drug, with or with…

This early-phase study tests a new treatment called iExosomes for people with metastatic pancreatic cancer that has a specific mutation in the KRAS gene (G12D). The treatment uses tiny particles from stem cells to deliver a molecule that blocks the mutated gene's activity. The st…

This early-phase study tests a new drug called DR-0202 in people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. About 96 participants wi…

This early-phase study tests a new drug that delivers radiation directly to cancer cells in people with advanced solid tumors (like lung, colon, head and neck, pancreatic, stomach, or kidney cancer) that have stopped responding to standard treatments. The main goals are to check …

This study tests a new treatment for people with advanced pancreatic cancer whose tumors have a specific genetic change (KRAS G12V) and a certain immune type (HLA-A*11:01). The treatment uses the patient's own immune cells, modified in a lab to recognize and attack cancer cells. …

This study tests a drug called tegavivint in children, teens, and young adults (ages 1 to 30) whose solid tumors have returned or are not responding to standard treatments. The drug works by blocking a key signal that tells cancer cells to grow. The trial aims to find the safest …

This study tests a new drug called AZD4360 in adults with advanced solid tumors, including stomach, gastroesophageal junction, bile duct, and pancreatic cancers that have not responded to prior treatments. The main goals are to find a safe dose and check for side effects, while a…

This early-phase trial tests a new drug called PTM-101 given alongside standard chemotherapy for people with pancreatic cancer that is either borderline resectable or locally advanced. The goal is to see if the combination is safe and can shrink tumors enough to allow surgery. Ab…

This study tests an experimental drug called PF-08046050 in people with advanced solid tumors (cancers that have spread or can't be removed). The drug is designed to stick to cancer cells and kill them. The main goal is to check safety and find the right dose. About 914 adults wi…

This study tests a new treatment that delivers a powerful, short-range radioactive particle directly to cancer cells that have a protein called FAP on their surface. The therapy is given in two steps: first a low-dose imaging version to see if the tumor takes up the drug, then a …

This is an early-stage study testing a new type of personalized cell therapy for adults with advanced solid tumors that have a specific genetic change called KRAS G12D. Doctors will collect a patient's own immune cells, genetically modify them in a lab to recognize and attack can…

This early-stage study is testing an experimental drug called AZD5863 in adults with advanced stomach, esophageal junction, esophageal, or pancreatic cancers that have spread. The drug is designed to work like a bridge, connecting the patient's own immune cells to cancer cells to…

This study is testing whether a new PET imaging tracer called [18F]FAPI-74 can find tumors as well as or better than the standard tracer in adults with certain cancers (like pancreatic, ovarian, or lung cancer). Participants will get both types of scans to compare how many tumors…

This study tests whether a special MRI scan can detect tiny liver metastases that standard CT scans miss in people newly diagnosed with pancreatic cancer. About 120 participants will get both a CT and an MRI before any treatment. If MRI proves better at finding these hidden spots…

This study is testing a new blood test that looks for tiny particles called exosomes to find pancreatic cancer early. Researchers will study 2,000 people, including those with and without the disease, to see how accurate the test is. If successful, it could lead to earlier diagno…

This study tests a new type of MRI scan that uses a special contrast agent (hyperpolarized carbon-13 pyruvate) to see how pancreatic tumors process nutrients. The goal is to predict whether treatment is working earlier than standard scans. The study involves 70 adults with advanc…

This study tests a new imaging agent called [18F]FPyQCP for PET scans to detect five types of cancer: colorectal, ovarian, gastric, invasive lobular breast, and pancreatic. About 71 adults will receive a single dose of the agent to check its safety and how well it finds cancer, e…

This study tests a new imaging agent (GEH300079) used with a PET/CT scan to find peritoneal carcinomatosis—cancer that has spread to the lining of the abdomen—in people with colorectal, gastric, ovarian, or pancreatic cancers. About 175 adults with known or suspected spread will …

This study is testing a new screening program to find pancreatic cancer earlier in people at high risk. Participants are 50 to 85 years old with new-onset diabetes and a high risk score. They will get repeated CT scans reviewed by artificial intelligence and blood tests. The goal…

This study enrolls 5,000 people at high risk for pancreatic cancer to collect blood, pancreatic juice, and medical images over 10 years. Researchers will use these samples to develop and validate tests for early detection, including AI-assisted analysis. Participants must be 18 o…

This study looks at whether genetic information from tumors can help doctors choose the right treatment for pancreatic cancer. About 200 people with early or locally advanced pancreatic cancer will give blood and tissue samples while receiving standard chemotherapy. Researchers w…

This study is developing a blood test that looks at tiny particles called exosomes to predict how well pancreatic cancer will respond to chemotherapy given before surgery. Researchers will analyze blood samples from 200 patients who have already had chemotherapy and surgery. The …

This study follows 4,000 adults aged 30 and older who have at least one pancreatic cyst. The goal is to track which cysts turn into cancer and which stay harmless. By collecting data over time, researchers hope to create better guidelines to avoid unnecessary surgeries while catc…

This study compares two surgical methods for removing part of the pancreas and nearby organs in people with pancreatic or related cancers. About 90 adults will be randomly assigned to either laparoscopic (keyhole) or open surgery. The goal is to see which approach leads to fewer …

This study is for people at high risk of pancreatic cancer, such as those with a strong family history or certain genetic conditions. Researchers will use MRI and endoscopic ultrasound to screen 700 participants for early signs of the disease. The goal is to find cancer earlier, …

This early-phase study is testing a new substance called RAD301 in 9 healthy volunteers and people with certain cancers (pancreatic, lung, esophageal, cervical, endometrial, or ovarian). The goal is to see how the body absorbs and handles the radiation from RAD301, and whether it…

This study looks at whether a simple blood test (ctDNA) can tell doctors early on if chemotherapy is shrinking tumors in people with metastatic pancreatic cancer. Currently, doctors wait about 8 weeks for a scan to check, but this test might give answers in just 4 weeks. About 50…

This study aims to find better ways to detect pancreatic cancer early in people who are at higher risk due to family history or certain gene changes. Researchers will follow 20,000 volunteers over time to see who develops the disease. The goal is to improve screening and preventi…